Aureus Asset Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $965K | Sell |
22,603
-232,760
| -91% | -$12.6M | 0.06% | 124 |
|
|
2026
Q1 | $16M | Buy |
+255,363
| New | +$20.4M | 1.07% | 28 |
|
|
2024
Q2 | – | Sell |
-3,769
| Closed | -$258K | – | 204 |
|
|
2024
Q1 | $258K | Sell |
3,769
-57
| -1% | -$3.67K | 0.02% | 166 |
|
|
2023
Q4 | $221K | Buy |
+3,826
| New | +$204K | 0.02% | 178 |
|
|
2023
Q3 | – | Sell |
-4,245
| Closed | -$230K | – | 195 |
|
|
2023
Q2 | $230K | Hold |
4,245
| – | – | 0.02% | 159 |
|
|
2023
Q1 | $212K | Sell |
4,245
-1,320
| -24% | -$62.2K | 0.02% | 168 |
|
|
2022
Q4 | $257K | Hold |
5,565
| – | – | 0.02% | 157 |
|
|
2022
Q3 | $216K | Sell |
5,565
-5,600
| -50% | -$225K | 0.02% | 157 |
|
|
2022
Q2 | $416K | Buy |
11,165
+344
| +3% | +$14K | 0.03% | 133 |
|
|
2022
Q1 | $479K | Hold |
10,821
| – | – | 0.03% | 148 |
|
|
2021
Q4 | $460K | Buy |
10,821
+925
| +9% | +$38.9K | 0.03% | 136 |
|
|
2021
Q3 | $429K | Sell |
9,896
-350
| -3% | -$15.5K | 0.03% | 141 |
|
|
2021
Q2 | $438K | Buy |
+10,246
| New | +$431K | 0.03% | 149 |
|
|
2021
Q1 | – | Sell |
-667,048
| Closed | -$24M | – | 182 |
|
|
2020
Q4 | $24M | Buy |
667,048
+9,985
| +2% | +$360K | 2.02% | 20 |
|
|
2020
Q3 | $25.1M | Buy |
657,063
+29,720
| +5% | +$1.15M | 2.38% | 16 |
|
|
2020
Q2 | $22M | Buy |
627,343
+7,530
| +1% | +$271K | 2.4% | 16 |
|
|
2020
Q1 | $20.2M | Sell |
619,813
-17,210
| -3% | -$672K | 2.81% | 15 |
|
|
2019
Q4 | $28.8M | Sell |
637,023
-9,855
| -2% | -$412K | 3.22% | 8 |
|
|
2019
Q3 | $26.3M | Sell |
646,878
-7,090
| -1% | -$300K | 3.28% | 9 |
|
|
2019
Q2 | $28.1M | Buy |
653,968
+20,480
| +3% | +$788K | 3.46% | 4 |
|
|
2019
Q1 | $24.3M | Sell |
633,488
-5,810
| -0.9% | -$222K | 3.22% | 6 |
|
|
2018
Q4 | $22.6M | Buy |
639,298
+7,000
| +1% | +$254K | 3.55% | 5 |
|
|
2018
Q3 | $24.3M | Buy |
632,298
+30
| +0% | +$1.05K | 3.1% | 5 |
|
|
2018
Q2 | $20.7M | Buy |
632,268
+22,580
| +4% | +$681K | 2.84% | 12 |
|
|
2018
Q1 | $16.7M | Buy |
609,688
+4,480
| +0.7% | +$122K | 2.5% | 17 |
|
|
2017
Q4 | $15M | Buy |
605,208
+19,870
| +3% | +$548K | 2.32% | 20 |
|
|
2017
Q3 | $17.1M | Buy |
585,338
+5,420
| +0.9% | +$150K | 2.7% | 8 |
|
|
2017
Q2 | $16.1M | Sell |
579,918
-135,640
| -19% | -$3.6M | 2.7% | 9 |
|
|
2017
Q1 | $18.9M | Buy |
715,558
+4,838
| +0.7% | +$118K | 3.28% | 1 |
|
|
2016
Q4 | $15.4M | Buy |
710,720
+16,704
| +2% | +$364K | 3.01% | 5 |
|
|
2016
Q3 | $16.5M | Buy |
694,016
+2,075
| +0.3% | +$49.5K | 3.3% | 3 |
|
|
2016
Q2 | $16.2M | Buy |
691,941
+17,585
| +3% | +$380K | 3.48% | 2 |
|
|
2016
Q1 | $12.7M | Buy |
674,356
+43,281
| +7% | +$760K | 2.77% | 13 |
|
|
2015
Q4 | $11.6M | Buy |
631,075
+83,839
| +15% | +$1.5M | 2.61% | 16 |
|
|
2015
Q3 | $8.98M | Buy |
547,236
+31,336
| +6% | +$536K | 2.23% | 20 |
|
|
2015
Q2 | $9.13M | Buy |
515,900
+109,680
| +27% | +$1.96M | 1.92% | 23 |
|
|
2015
Q1 | $7.21M | Buy |
+406,220
| New | +$6.42M | 1.66% | 30 |
|
Other funds holding BSX
Aureus Asset Management's BSX Position: Q2 2026 in Review
Aureus Asset Management reduced its Boston Scientific (BSX) stake by 91% in Q2 2026, selling an estimated $12.6M and leaving 22,603 shares worth $965K. The position accounts for 0.06% of the portfolio, ranked #124.
Aureus Asset Management first reported a position in BSX in Q1 2015 and has held it in 37 quarters since. The position peaked at $28.8M in Q4 2019. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Aureus Asset Management held 22,603 shares of Boston Scientific worth $965K as of Q2 2026.
- Aureus Asset Management sold 232,760 Boston Scientific shares in Q2 2026, an estimated $12.6M.
- Boston Scientific made up 0.06% of Aureus Asset Management's portfolio in Q2 2026, its #124 holding.
- Aureus Asset Management first reported a position in Boston Scientific in Q1 2015 and has held it in 37 quarters since.
- Aureus Asset Management's Boston Scientific position peaked at $28.8M in Q4 2019.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Aureus Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.